Paul Berns is a longtime pharma and biotech operator who led companies like Anacor Pharmaceuticals (sold to Pfizer for over $5 billion) and was an early architect behind Humira's success at Abbott, giving him unusually direct large-scale drug commercialization experience for a venture investor. Rather than serving as a traditional board-level investor, he frequently co-founds and serves as CEO or executive chairman of ARCH-backed companies like Neumora Therapeutics, where he simultaneously holds roles as ARCH managing director, company co-founder, chairman, and CEO. Paul Berns is a longtime pharma and biotech operator who led companies like Anacor Pharmaceuticals (sold to Pfizer for over $5 billion) and was an early architect behind Humira's success at Abbott, giving him unusually direct large-scale drug commercialization experience for a venture investor. Rather than serving as a traditional board-level investor, he frequently co-founds and serves as CEO or executive chairman of ARCH-backed companies like Neumora Therapeutics, where he simultaneously holds roles as ARCH managing director, company co-founder, chairman, and CEO.